The Medical College of Wisconsin, Inc.

Aix-Marseille Université

National Institutes of Health (nih)

Ming You

Balaraman Kalyanaraman

Micael J Hardy

Jacek Michal Zielonka

Michael A James

Olivier Ouari

Gang Cheng

Oliver Ouari

Haris G Vikis

Jing Pan

Ronald Lubet

Yian Wang

Donghai Xiong

A method of determining a patient's HPD status comprising the steps of a) examining a patient tumor sample for the expression level of HPD-diagnostic biomarkers, and b) determining whether the signature of the biomarkers is similar to that of a HPD positive signature is disclosed.

Gene expression signature of hyperprogressive disease (HPD) in patients after anti-PD-1 immunotherapy

The present invention provides mito-honokiol or mito-magnolol compounds, pharmaceutical compositions thereof, and methods of using the mito-honokiol or mito-magnolol compounds in the treatment of cancer.

Mito-honokiol compounds and methods of synthesis and use thereof

The present disclosure provides compositions and methods of eliciting an anti-tumor immune response and treating cancer comprising at least one peptide of KRAS.

KRAS peptide vaccine compositions and method of use

The present invention provides mito-honokiol compounds, pharmaceutical compositions thereof, and methods of using the mito-honokiol compounds in the treatment of cancer.

Provided herein are compositions for reducing CLPTM1L expression in a cell as well as methods for using such compositions to treat or prevent cancer in a subject. In particular, compositions comprising RNAi-inducing constructs targeted to CLPTM1L and methods of administering such compositions to a subject to treat or prevent a disease or condition associated with CLPTM1L over-expression (e.g., lung cancer) are provided herein.

Targeting CLPTM1L by RNA interference for treatment and prevention of cancer

Growing community of inventors

Elm Grove, WI, United States of America

Ming You